News & Updates

New drug applications approved by US FDA as of 1-15 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Repetitive transcranial magnetic stimulation (rTMS) has helped improve outcomes in most patients with treatment-resistant depression (TRD) treated within a local general hospital, according to retrospective study.

A single intranasal dose of the psychedelic mebufotenin benzoate helps improve symptoms in adults with treatment-resistant depression, with the benefit emerging as early as day 1 after dosing and persisting for 8 weeks, according to a phase IIb trial said to be the largest clinical evaluation to date of mebufotenin administered as a nose spray.

Poisoning is a unique driver of healthcare utilization among patients receiving care at the emergency department (ED) in Singapore. The Singhealth Toxicology Service offers insights in the management of this cohort, helping to prevent harm and improve resource allocation.

Older patients with major depressive disorder (MDD) treated with active theta-burst stimulation (TBS) show no significantly greater reduction in Hamilton Depression Rating Scale (HAM-D) scores than those who received sham stimulation at week 6, according to a study.

Magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) deliver similar effects on clinical outcomes in individuals with bipolar depression, reveals a study. However, MST is associated with fewer cognitive adverse effects.